Shots:
- The companies launch Semglee and Insulin Glargine as interchangeable biosimilars products to improve patients’ access with type 1 & 2 diabetes. Biocon and Viatris have co-developed both biosimilars products
- Both biosimilars products are available in a vial and prefilled pen presentations & will allow pharmacy level substitution for the reference product, Lantus across the US. Semglee is expected to be phased out at the end of 2021
- Viatris has established multiple options for patients including a patient assistance program to provide free products to eligible patients with financial need, Copay program for eligible commercially-insured patients along with other programs
Click here to read the full press release/ article | Ref: PR Newswire | Image: Viatris
The post Viatris and Biocon Launch Semglee (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn) for the Treatment of Diabetes in the US first appeared on PharmaShots.
